Autoimmune diseases affect over 4% of the world's population. Treatments are generally
palliative or use broad spectrum immunosuppressants to reduce symptoms and disease …

Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …

Autoimmune diseases affect many people worldwide. Current treatment modalities focus on
the reduction of disease symptoms using anti-inflammatory drugs which can lead to side …

Rheumatoid arthritis (RA) is a systemic autoimmune disease (AD) caused by the aberrant
attack of the immune system on its own joint tissues. Genetic and environmental factors are …

Tolerogenic nanoparticles (NPs) are rapidly being developed as specific immunotherapies
to treat autoimmune disease. However, many NP-based therapies conjugate antigen (Ag) …

Tolerogenic immunotherapy aims to blunt pathogenic inflammation without affecting
systemic immunity. However, the anti-inflammatory drugs and immunosuppressive biologics …

The development of nanomaterials to induce antigen-specific immune tolerance has shown
promise for treating autoimmune diseases. While PEGylation has been widely used to …

Autoimmune diseases are disorders of immune regulation where the mechanisms
responsible for self-tolerance break down and pathologic T cells overcome the protective …

Targeted immune tolerance is a coveted therapy for the treatment of a variety of autoimmune
diseases, as current treatment options often involve nonspecific immunosuppression …

The development of antidrug antibodies (ADAs) is a common cause for the failure of
biotherapeutic treatments and adverse hypersensitivity reactions. Here we demonstrate that …